CN101287758A - 作为肿瘤诊断和治疗的靶的丛蛋白d1 - Google Patents

作为肿瘤诊断和治疗的靶的丛蛋白d1 Download PDF

Info

Publication number
CN101287758A
CN101287758A CNA2006800303915A CN200680030391A CN101287758A CN 101287758 A CN101287758 A CN 101287758A CN A2006800303915 A CNA2006800303915 A CN A2006800303915A CN 200680030391 A CN200680030391 A CN 200680030391A CN 101287758 A CN101287758 A CN 101287758A
Authority
CN
China
Prior art keywords
plexin
antibody
cell
binding
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800303915A
Other languages
English (en)
Chinese (zh)
Inventor
W·P·J·林德斯
I·罗迪恩克
J·M·H·拉茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Original Assignee
Stichting Katholieke Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Universiteit filed Critical Stichting Katholieke Universiteit
Publication of CN101287758A publication Critical patent/CN101287758A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
CNA2006800303915A 2005-07-21 2006-07-20 作为肿瘤诊断和治疗的靶的丛蛋白d1 Pending CN101287758A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05076675.7 2005-07-21
EP05076675 2005-07-21

Publications (1)

Publication Number Publication Date
CN101287758A true CN101287758A (zh) 2008-10-15

Family

ID=37115996

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800303915A Pending CN101287758A (zh) 2005-07-21 2006-07-20 作为肿瘤诊断和治疗的靶的丛蛋白d1

Country Status (12)

Country Link
US (4) US20100119445A1 (https=)
EP (1) EP1907420B1 (https=)
JP (1) JP2009506985A (https=)
CN (1) CN101287758A (https=)
AU (1) AU2006271880A1 (https=)
BR (1) BRPI0613425A2 (https=)
CA (1) CA2615744C (https=)
DK (1) DK1907420T3 (https=)
ES (1) ES2632360T3 (https=)
IL (1) IL188688A0 (https=)
PL (1) PL1907420T3 (https=)
WO (1) WO2007009816A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914542B (zh) * 2009-04-28 2013-03-06 中国科学院化学研究所 用于不同亚型非小细胞肺癌分型的一种核酸适体及其筛选方法
CN106967789A (zh) * 2017-01-26 2017-07-21 上海长海医院 一种前列腺癌标志物plxna1及其应用
CN116459356A (zh) * 2023-04-24 2023-07-21 中国人民解放军总医院第一医学中心 用于动脉粥样硬化斑块早期预警和动态监测的多模态分子成像纳米探针及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181035A1 (en) * 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
US8512944B2 (en) * 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
EP2385121A1 (en) * 2010-05-06 2011-11-09 Netris Pharma Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
CA2912801A1 (en) * 2013-05-17 2014-11-20 Medimmune, Llc Receptors for b7-h4
US11066462B2 (en) 2014-12-11 2021-07-20 Citryll B.V. Method for the treatment of idiopathic pulmonary fibrosis
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
EP3693380A1 (en) 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
CN117659171B (zh) * 2022-09-07 2024-10-22 东莞市朋志生物科技有限公司 抗HBeAg抗体或其功能性片段、检测HBeAg的试剂和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
WO2001014420A2 (en) * 1999-08-25 2001-03-01 University Of Torino Novel members of the plexin family and uses thereof
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2001090190A2 (en) * 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
SE0203137D0 (sv) * 2002-10-24 2002-10-24 Karolinska Innovations Ab Drug target in cancer therapy
AU2003292231A1 (en) * 2002-12-12 2004-06-30 Novartis Ag Methods for diagnosing and treating schizophrenia
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
EP1679372B1 (en) * 2003-10-30 2009-02-18 Kazusa DNA Research Institute Foundation Novel plexin polypeptide, dna encoding the same and use thereof
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914542B (zh) * 2009-04-28 2013-03-06 中国科学院化学研究所 用于不同亚型非小细胞肺癌分型的一种核酸适体及其筛选方法
CN106967789A (zh) * 2017-01-26 2017-07-21 上海长海医院 一种前列腺癌标志物plxna1及其应用
WO2018137436A1 (zh) * 2017-01-26 2018-08-02 上海长海医院 一种前列腺癌标志物plxna1及其应用
CN116459356A (zh) * 2023-04-24 2023-07-21 中国人民解放军总医院第一医学中心 用于动脉粥样硬化斑块早期预警和动态监测的多模态分子成像纳米探针及其应用
CN116459356B (zh) * 2023-04-24 2024-03-19 中国人民解放军总医院第一医学中心 用于动脉粥样硬化斑块早期预警和动态监测的多模态分子成像纳米探针及其应用
WO2024165076A1 (zh) * 2023-04-24 2024-08-15 中国人民解放军总医院第一医学中心 用于动脉粥样硬化斑块早期预警和动态监测的多模态分子成像纳米探针及其应用

Also Published As

Publication number Publication date
DK1907420T3 (en) 2017-07-17
EP1907420B1 (en) 2017-04-05
CA2615744C (en) 2018-03-27
US20100119445A1 (en) 2010-05-13
US9988449B2 (en) 2018-06-05
CA2615744A1 (en) 2007-01-25
JP2009506985A (ja) 2009-02-19
PL1907420T3 (pl) 2017-09-29
WO2007009816A2 (en) 2007-01-25
US9422358B2 (en) 2016-08-23
BRPI0613425A2 (pt) 2012-10-30
US20120321554A1 (en) 2012-12-20
US20160311900A1 (en) 2016-10-27
AU2006271880A1 (en) 2007-01-25
WO2007009816A3 (en) 2007-03-29
IL188688A0 (en) 2008-08-07
US20180319882A1 (en) 2018-11-08
ES2632360T3 (es) 2017-09-12
EP1907420A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
US9988449B2 (en) Plexin D1 as a target for tumor diagnosis and therapy
ES2286831T3 (es) Anticuerpos para el dominio ed-b de fibronectina, la construccion de estos y sus usos.
JP5957637B2 (ja) 抗ＴｉｓｓｕｅＦａｃｔｏｒモノクローナル抗体
AU2012292120B2 (en) Novel anti-CXCR4 antibody and its use for the detection and diagnosis of cancer
CN114106099A (zh) 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
JP2009542810A (ja) Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
CN101432305A (zh) 运铁蛋白受体抗体
CN101671393A (zh) 血管生成素-2的特异结合剂
CN104661677A (zh) 抗Jagged 1/Jagged 2交叉反应抗体、可活化的抗Jagged抗体及其使用方法
US20170267755A1 (en) Isolated anti-mesothelin antibodies, conjugates and uses thereof
JP2013538191A5 (ja) 病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗ＤＥｓｐＲ阻害剤
JP2013522167A (ja) ｕＰＡＲ結合剤及びその使用方法
Brack et al. Molecular targeting of angiogenesis for imaging and therapy
JP2007523650A5 (https=)
Dhaouadi et al. Novel human tenascin-C function-blocking camel single domain nanobodies
Rahn et al. Development of a peptide-based delivery platform for targeting malignant brain tumors
CN103415619B (zh) 抗-c-met抗体及其使用方法
Sanchez-Martin et al. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
Putelli et al. A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo
US10155810B2 (en) Provasopressin antagonists and uses thereof
US20210155709A1 (en) Antibodies anti tumor associated antigens and method for obtaining them
RU2706959C2 (ru) Антитело к igf-1r и его применение для диагностики рака
CN110734494B (zh) 抗tspan8单克隆抗体及其用途
MX2008000919A (en) Plexin d1 as a target for tumor diagnosis and therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124346

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20081015

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124346

Country of ref document: HK